Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma (NHL)
MeSH terms: Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell
Intervention: Bendamustine hydrochloride; Ofatumumab
Intervention description: Bendamustine will be administered at 90 mg/m^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.; Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
Intervention MeSH terms: Bendamustine Hydrochloride; Ofatumumab
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 50.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The primary objective of the study is to determine the efficacy, as measured by overall
      response (complete response + partial response) of bendamustine in combination with
      ofatumumab in previously untreated patients with indolent B-Cell Non-Hodgkin's Lymphoma
      (NHL).
    

Eligibility criteria:

        Key Inclusion Criteria:

          -  The patient has histopathologic confirmation of one of the protocol-specific CD20+
             B-cell non-Hodgkin's lymphomas. Tissue diagnostic procedures must be performed within
             6 months of study entry and with biopsy material available for review.

          -  The patient meets 1 of the following need-for-treatment criteria:

               1. Presence of at least 1 of the following B-symptoms:

                    -  fever (>38ºC) of unclear etiology

                    -  night sweats

                    -  weight loss of greater than 10% within the prior 6 months

               2. large tumor mass (bulky disease) characterized by lymphomas with a diameter of
                  more than 3 cm in 3 or more regions or by a lymphoma with a diameter of more than
                  7 cm in 1 region

               3. presence of lymphoma-related complications

               4. hyperviscosity syndrome due to monoclonal gammopathy

          -  The patient's tumor is verified to be CD20+ positive from current or previous
             excisional or incisional tissue diagnostic procedures performed within 6 months of
             study entry.

          -  The screening phase CT scan (based on local evaluation) shows:

          -  2 or more clearly demarcated lesions with a largest diameter ≥1.5 cm, or

          -  1 clearly demarcated lesion with a largest diameter ≥2.0 cm

          -  The patient was not previously treated for indolent lymphoma (with the exception of a
             single course of local radiation therapy not exceeding 2 adjacent lymph node regions).

          -  The patient has adequate hematologic and hepatic function.

          -  The patient has Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or
             2.

          -  The patient has serum creatinine of 2.0 mg/dL or less or creatinine clearance of 30
             mL/min or more, based on the Cockcroft-Gault method, or from a 24-hour urine
             collection.

          -  The patient is willing to comply with contraception requirements.

        Key Exclusion Criteria:

        The patient:

          -  Has small lymphocytic lymphoma or mantle cell lymphoma.

          -  Has documented history of central nervous system (CNS) lymphomatous involvement.

          -  Has or has had an active malignancy, other than NHL, within the past 3 years except
             for localized prostate cancer without evidence of bone metastases, bladder, cervical,
             or breast carcinoma in-situ, or non-melanoma skin cancer .

          -  Has New York Heart Association (NYHC) Class III or IV heart failure, uncontrolled
             arrythmias or unstable angina, electrocardiographic evidence of active ischemia or
             active conduction system abnormalities, or myocardial infarction within the last 6
             months.

          -  Has known human immunodeficiency virus (HIV) infection.

          -  Has acute or chronic hepatitis B or hepatitis C infection.

          -  Is a pregnant or lactating woman. (Any women becoming pregnant during the study will
             be withdrawn from the study.)

          -  Has any serious uncontrolled, medical or psychological disorder that would impair the
             ability of the subject to receive study drugs.

          -  Has received another investigational agent within 30 days of study entry.

          -  Has known hypersensitivity to mannitol.

          -  Has Ann Arbor stage I disease.